ArticlemedRxiv : the preprint server for health sciences2024

Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.

Veronica Rendo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.